Indeed, EPM301 normalized obesity-associated elevation in liver enzyme levels (AST, ALT, and ALP; Figure 4A–C) as well as reduced liver fat accumulation and hepatic triglycerides (Figure 4D,E), demonstrating the ability of EPM301 to ameliorate DIO-induced hepatic steatosis. The gene discussed is GPT; the disease is fatty liver disease.